The earnings call was notably positive, highlighting significant revenue growth, successful patient outcomes, new market expansions, and financial stability. While there were concerns about the lack of international sales, the overall progress and achievements outweighed this challenge.

Company Guidance

During the third quarter of fiscal year 2025, NeuroOne Medical Technologies Corporation provided guidance indicating a strong financial performance with product revenue increasing by 105% to $1.7 million, and gross margins improving from 34.1% in Q3 FY 2024 to 53.9%. The company reiterated its fiscal year 2025 guidance, projecting product revenue between $8 million and $10 million, marking an increase of 132% to 190% over fiscal year 2024, with gross margin expectations raised to 50-53%, up from the initial 47-51% forecast. The company remains debt-free and expects to be funded through at least fiscal year 2026, thanks to an $8.2 million oversubscribed financing raised in April. Additionally, NeuroOne highlighted its strategic initiatives in pain management, including a submitted 510(k) for trigeminal neuralgia treatment and developments in spinal cord stimulation, which could open new market opportunities. The company also indicated progress in its drug delivery system and IP portfolio, including a notice of allowance for a novel manufacturing method and its first international patent.

Significant Revenue and Gross Margin Growth

Product revenue increased 105% to $1.7 million and product gross margins increased to 53.9% in the third quarter of fiscal 2025 compared to 34.1% in the third quarter of fiscal 2024.

Successful Patient Outcomes

First patient reached the 1-year seizure freedom milestone with the OneRF ablation system, showing improved quality of life.

Debt-Free Status and Financial Stability

The company remains debt-free and is funded through fiscal year 2026, aided by an oversubscribed capital raise of $8.2 million.

Expansion into New Markets

Submitted 510(k) for FDA clearance for trigeminal neuralgia treatment and pursuing opportunities in pain management and spinal cord stimulation.

Intellectual Property and Management Strengthening

Received a notice of allowance for a novel manufacturing method and granted the first international patent for spinal cord stimulation electrode.

Decreased Operating Expenses and Improved Net Loss

Total operating expenses decreased 9% in the third quarter, and net loss improved to $1.5 million compared to $2.8 million in the previous year.

NeuroOne Medical Technologies (NMTC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NMTC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Dec 10, 2025	2025 (Q4)	-0.04 / -	-0.11	―	―	―
Aug 14, 2025	2025 (Q3)	-0.05 / -0.03	-0.1	70.00% (+0.07)	―
May 13, 2025	2025 (Q2)	-0.09 / -0.07	-0.11	36.36% (+0.04)	―
Feb 12, 2025	2025 (Q1)	- / 0.06	-0.14	142.86% (+0.20)	―
Dec 17, 2024	2024 (Q4)	- / -0.11	-0.171	35.67% (+0.06)	―
Aug 14, 2024	2024 (Q3)	-0.09 / -0.10	-0.2	50.00% (+0.10)	―
May 14, 2024	2024 (Q2)	-0.09 / -0.11	-0.21	47.62% (+0.10)	―
Feb 13, 2024	2024 (Q1)	-0.14 / -0.14	-0.11	-27.27% (-0.03)	―
Dec 14, 2023	2023 (Q4)	-0.17 / -0.17	-0.08	-113.75% (-0.09)	―
Aug 14, 2023	2023 (Q3)	-0.20 / -0.20	-0.17	-17.65% (-0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NMTC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$0.86	$0.83	-3.49%
May 13, 2025	$0.62	$0.64	+3.23%
Feb 12, 2025	$1.09	$1.12	+2.75%
Dec 17, 2024	$0.76	$0.79	+3.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does NeuroOne Medical Technologies (NMTC) report earnings?

NeuroOne Medical Technologies (NMTC) is schdueled to report earning on Dec 10, 2025, Before Open (Confirmed).

What is NeuroOne Medical Technologies (NMTC) earnings time?

NeuroOne Medical Technologies (NMTC) earnings time is at Dec 10, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NMTC EPS forecast?

NMTC EPS forecast for the fiscal quarter 2025 (Q4) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing